IL6 and metabolic syndrome: Although the clinical significance of these associations may be low, as dyslipidemia secondary to TCZ treatment has not been linked to an increased risk of cardiovascular events [39–43], the interplay between lipid profiles and inflammatory pathways, such as IL-6, has been extensively described [42, 44–46].